In this article, I will feature one biotech company that has seen intensive insider buying during the last 30 days. Intensive insider buying can be defined by the following three criteria:
- The stock is purchased by three or more insiders within one month.
- The stock is sold by no insiders in the month of intensive purchasing.
- At least two purchasers increase their holdings by more than 10%.
Repros Therapeutics (RPRX), a development stage biopharmaceutical company, engages in the development of new drugs to treat hormonal and reproductive system disorders.
Insider buying during the last 30 days
Here is a table of Repros Therapeutics' insider-trading activity during the last 30 days by insider.
|Name||Title||Trade Date||Shares Purchased||Current Ownership||Increase In Shares|
|Daniel Cain||Director||Nov 12||500||1,000 shares||+100%|
|Joseph Podolski||CEO||Oct 25||3,000||58,945 shares||+5.4%|
|Katherine Anderson||CFO||Oct 25||1,000||6,375 shares||+18.6%|
There have been 4,500 shares purchased by insiders during the last 30 days.
Insider buying by calendar month
Here is a table of Repros Therapeutics' insider-trading activity by calendar month.
|Month||Insider buying / shares||Insider selling / shares|
There have been 6,500 shares purchased and there have been zero shares sold by insiders this year. The month of October has seen the most insider buying.
Repros reported the third-quarter financial results on November 7 with the following highlights:
|Net loss||$6.0 million|
Pipeline and upcoming milestones
Repros' pipeline consists of the following:
|Androxal||For men of reproductive age with low testosterone due to secondary hypogonadism.|
|Proellex||For women with uterine fibroids and endometriosis.|
Repros has the following upcoming milestones:
|Androxal||NDA-submission in Q4/2014|
|Proellex||Phase 2b study start in early 2014|
Androxal's competitors include the following:
|AndroGel||Abbott Laboratories (ABT)|
|Testim||Auxilium Pharmaceuticals (AUXL)|
Proellex' competitors include the following:
Here is a table of these competitors' insider-trading activities this year.
|Company||Insider buying / shares||Insider selling / shares|
Only Repros has seen intensive insider buying during the last 30 days.
There have been three different insiders buying Repros and there have not been any insiders selling Repros during the last 30 days. Two of these three insiders increased their holdings by more than 10%. Repros has an insider ownership of 0.30%.
There are five analyst buy ratings, zero neutral ratings, and zero sell ratings with an average price target of $32.00. The stock plunged on October 23, which was due to the delay in the potential approval of Androxal. The insiders started buying shares after this drop in the share price. I believe the stock could be a good speculative pick from the current price level based on the intensive insider buying.